HCPCS | Generic Name (Ascending) | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|---|
J9050 | Carmustine | Bicnu | 100 mg | Chemotherapy | Alkylating Agent | Nitrosourea | No | 1977 | Jan. 1, 1984 | In Use | ||
J9052 | Carmustine (Accord) | Carmustine | 100mg | Chemotherapy | Alkylating Agent | Nitrosurea | No | 2022 | Dec. 7, 2023 | In Use | ||
NA | Carmustine wafer | Gliadel | 7.7mg | Chemotherapy | Alkylating Agent | Nitrosourea | No | 2012 | In Use | |||
NA | Cedazuridine and Decitabine | Inqovi | 100mg, 35mg | Chemotherapy | Antimetabolite | Pyrimidine Analog + CDA Inhibitor | Yes | 2020 | In Use | |||
J9113 | Cemiplimab-rwlc | Libtayo | 1mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2018 | Oct. 1, 2019 | In Use | ||
NA | Ceritinib | Zykadia | 150 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2014 | In Use | |||
NA | Cervarix | Human papillomavirus vaccine | 20 mcg vaccine | Ancillary Therapy | Protective Agent | HPV Vaccine | No | 2009 | 2016 | In Use | ||
C9215 | Cetuximab | Erbitux | 10 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2004 | Feb. 12, 2004 | Dec. 31, 2004 | No Longer Used | |
J9055 | Cetuximab | Erbitux | 10 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2004 | Jan. 1, 2005 | In Use | ||
J8999 | Chemotherapy - non specific | Prescription drug, oral, chemotherapeutic NOS | NA | Chemotherapy | Yes | In Use | ||||||
J9999 | Chemotherapy - non specific | Not otherwise classified, antineoplastic drugs | NA | Chemotherapy | No | In Use | ||||||
S0172 | Chlorambucil | Leukeran | 2 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1957 | Jan. 1, 2002 | In Use | ||
NA | Chlorotrianisene | Anisene | 12 mg | Hormonal Therapy | Estrogen | Yes | 1992 | 1997 | In Use | |||
Q2056 | Ciltacabtagene autoleucel | CARVYKTI | up to 100 million | Immunotherapy | CAR-T | No | 2022 | Sept. 27, 2022 | In Use | |||
C9098 | Ciltacabtagene autoleucel | CARVYKTI | up to 100 million | Immunotherapy | CAR-T | No | 2022 | March 25, 2022 | Sept. 27, 2022 | No Longer Used | ||
J9060 | Cisplatin | Platinol, Platinol-AQ | 10 mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 1978 | Jan. 1, 1984 | In Use | ||
J9062 | Cisplatin | Platinol, Platinol-AQ | 50 mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 1978 | Jan. 1, 1982 | Dec. 31, 2010 | No Longer Used | |
C9418 | Cisplatin | Platinol, Platinol-AQ | 10 mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 1978 | Jan. 1, 2004 | Dec. 31, 2005 | No Longer Used | |
J9065 | Cladribine | Cladribine | per 1 mg | Chemotherapy | Antimetabolite | Purine Analog | No | 1993 | Jan. 1, 1995 | In Use | ||
J9027 | Clofarabine | Clolar | 1 mg | Chemotherapy | Antimetabolite | Purine Analog | No | 2004 | Jan. 1, 2006 | In Use | ||
J9057 | Copanlisib | Aliqopa | 1mg | Chemotherapy | Enzyme Inhibitor | PI3K | No | 2017 | In Use | |||
NA | Cortisone Acetate | Cortisone Acetate | 25 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1951 | In Use | |||
NA | Crizotinib | Xalkori | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2011 | In Use | |||
NA | Crizotinib | Xalkori | 250 mg | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Yes | 2011 | In Use | |||
J9091 | Cyclophosphamide | Cyclophosphamide | 1 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan. 1, 1994 | Jan. 1, 2011 | No Longer Used |
Found 716 results in 0 milliseconds — Export these results
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.